CAGRILINTIDE

Home CAGRILINTIDE

GLP-3 RETA

£94.99

TB-500 (Thymosin Beta-4)

£32.99

CAGRILINTIDE

~~£69.99~~ £49.99

– Amylin Analogue Peptide for Metabolic Research(Cagrilintide) | 5mg Vial | Ultra-Pure | ≥99% Peptide-Grade Purity🔬 High-Purity Research Peptide – Synthesized for reproducible laboratory use🧪 Verified for Quality – HPLC Tested, COA Provided, Third-Party Tested📚 Backed by Scientific Literature – Research supports weight regulation and glycemic control Chemical Information• Synonyms:...

SKU :

Why Choose Us ?

Maxx Labs delivers trusted quality, expert support, and reliable service—so your research stays precise, professional, and on track.

Returns

All products are sold strictly for research use. Returns are only accepted if items arrive damaged, defective, or incorrect—please contact us within 7 days of delivery.

Shipping

We offer next working day UK shipping for £4.99. Orders over £100 qualify for free shipping—fast, reliable delivery every time.

– Amylin Analogue Peptide for Metabolic Research
(Cagrilintide) | 5mg Vial | Ultra-Pure | ≥99% Peptide-Grade Purity
🔬 High-Purity Research Peptide – Synthesized for reproducible laboratory use
🧪 Verified for Quality – HPLC Tested, COA Provided, Third-Party Tested
📚 Backed by Scientific Literature – Research supports weight regulation and glycemic control

Chemical Information
• Synonyms: Cagrilintide
• CAS Number: 1415456-99-3
• Molecular Formula: C₁₉₄H₃₁₂N₅₄O₅₉S₂
• Form: Lyophilized powder, 5mg per vial
• Purity: ≥99% (Peptide-grade)
• Storage: Store at 2–8°C in a dry, shaded place

Description
Cagrilintide is a long-acting amylin analogue studied for its role in weight regulation and glycemic control through activation of amylin and calcitonin receptors.

As an analogue of the hormone amylin, it regulates satiety, gastric emptying, and glucose metabolism, making it a promising candidate for obesity and diabetes research.

Research Findings & Scientific Insights
📉 Obesity & Weight Loss
Clinical studies demonstrate significant body weight reduction, with up to 15.6% loss in a 32-week Phase II trial when combined with semaglutide.
📊 Glucose Regulation
Cagrilintide lowers HbA1c levels in type 2 diabetes models, indicating potential for glycemic management.
🩺 Potential Benefits Observed in Research Models:
• Enhanced satiety and reduced food intake
• Improved glucose control
• Synergistic effects with GLP-1 agonists
🌐 Clinical Insights
Combined with GLP-1 agonists, Cagrilintide amplifies appetite suppression and metabolic benefits in preclinical and clinical studies.

Product Assurance
✅ HPLC Verified – Ensuring ≥99% purity
✅ COA Provided – On Request
✅ Manufactured in a GMP-Certified Facility - Developed & Dispatched in the UK
✅ Third-Party Testing Covered – Independent Verification Available on Request
✅ Cold Chain Express Delivery – Ensuring Potency, Integrity & Safe Arrival

⚠️ For Research Use Only
Cagrilintide is supplied strictly for scientific research and analytical purposes only. This compound is not approved for human consumption, therapeutic use, or veterinary applications. All handling should be performed by qualified professionals in accordance with laboratory safety protocols.

⚠️ For Research Use Only – Not for Human Consumption
This product is intended strictly for laboratory research purposes and is not approved for human or veterinary use, therapeutic application, or diagnostic procedures. All handling must be performed by trained professionals in compliance with appropriate laboratory safety protocols and applicable regulations.

18+ Notice: This material is not for sale to individuals under the age of 18. By purchasing, you confirm that you are a qualified individual or acting on behalf of a qualified institution, and that the compound will be used exclusively for legitimate scientific investigation.

We acknowledge that in certain regions—particularly in countries outside of the United Kingdom, where manufacturing oversight and regulatory enforcement may be less stringent—there are isolated cases of individuals attempting to self-administer research compounds. We strongly discourage and explicitly warn against any such misuse. The self-experimentation of unapproved substances carries significant, unquantifiable risks and is both medically irresponsible and ethically unsound. Without proper analytical validation, GMP-level controls, and clinical context, the safety, quality, and pharmacological reliability of these materials cannot be assured.

All compounds must be handled in secure, controlled environments by competent personnel. Any deviation from these principles is contrary to responsible research practice and breaches both our terms of sale and the intended scientific use of these products.